27 completed, 5 terminated, 4 unknown, 2 active not recruiting. 11 Phase 3, 9 Not applicable, 7 Phase 2, 1 Phase 1, 1 Phase 4.
Follow Inappropriate ADH Syndrome: new trials by email Literature Review of Inappropriate ADH Syndrome trials Research Report on Inappropriate ADH Syndrome
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Protein Supplementation in Hyponatremia Due to the Syndrome of Inappropriate Antidiuresis Moltein PURE Protein Powder, Fluid restriction - Hyponatremia, Syndrome of Inappropriate Antidiuresis | Not applicable | Recruiting | University Hospital, Basel, Switzerland | 70 | 2025-04-14 | 2025-07-10 |
| Urea for Treatment of Hyponatremia in Patients With SIAD Unresponsive to Fluid Restriction urea - SIAD - Syndrome of Inappropriate Antidiuresis | Not applicable | Recruiting | University of Turin, Italy | 20 | 2024-09-12 | 2026-04-14 |
| Low-dose Tolvaptan for Inpatient Hyponatraemia. Tolvaptan - Hyponatremia, SIADH | Unknown | King's College Hospital NHS Trust | 180 | 2024-03-15 | 2024-03-08 | |
| Effects of Intravenous [Pyr1]Apelin-13 on Healthy Volunteers With Artificially Induced SIAD Placebo, Apelin Low Dose, Apelin High Dose - SIAD - Syndrome of Inappropriate Antidiuresis, Hyponatremia | Not applicable | Completed | University Hospital, Basel, Switzerland | 15 | 2024-03-01 | 2025-03-30 |
| Urea for Chronic Hyponatremia Urea - Hyponatremia, Inappropriate ADH Syndrome | Phase 2 | Terminated | Helbert Rondon Berrios, MD, MS | 2 | 2021-12-28 | 2024-05-20 |
| Asymptomatic Bacteriuria, Hyponatremia and Geri-atric Syndrome urine sample, Blood and urine sample - Asymptomatic Bacteriuria, Frailty | Not applicable | Completed | Universitair Ziekenhuis Brussel | 36 | 2021-10-30 | 2025-03-28 |
| Effect of Protein Supplementation on Plasma Sodium Levels and Urinary Urea Excretion in Patients With SIAD Protein supplementation, Oral urea - Syndrome of Inappropriate Antidiuresis (SIAD) | Not applicable | Completed | University Hospital, Basel, Switzerland | 18 | 2021-10-08 | 2023-02-21 |
| Samsca Post-marketing General Drug Use-results Survey in Patients With Hyponatremia in SIADH Tolvaptan (SAMSCA) - Antidiuretic Hormone, Inappropriate Secretion | Active not recruiting | Otsuka Pharmaceutical Co., Ltd. | 300 | 2021-03-29 | 2026-06-22 | |
| Effects of the SGLT2 Inhibitor Empagliflozin in Patients With Euvolemic and Hypervolemic Hyponatremia Empagliflozin 25 MG, Placebo - Hyponatremia, SIADH | Phase 4 | Completed | University Hospital, Basel, Switzerland | 113 | 2021-02-04 | 2026-09-22 |
| Urea Therapy for Hyponatremia in Subarachnoid Hemorrhage Urea, PLACEBO - Hyponatremia, Subarachnoid Hemorrhage | Not applicable | Active not recruiting | University Hospital, Grenoble | 52 | 2020-12-03 | 2025-04-16 |
| Changes in Serum Creatinine Levels Can Help Distinguish Hypovolemic From Euvolemic Hyponatremia Hyponatremia, Hypovolemia | Completed | Hospital San Carlos, Madrid | 122 | 2019-07-30 | 2022-08-03 | |
| SOFI: A Quality Improvement Project to Standardize Use of Intravenous Fluids in Hospitalized Pediatric Patients Education, clinical decision support tools - Intravenous Fluids, Fluid and Electrolyte Imbalance | Not applicable | Completed | Seattle Children's Hospital | 106 | 2019-04-01 | 2021-04-29 |
| Effects of the SGLT2-inhibitor Empagliflozin on Patients With Chronic SIADH - the SANDx Study Empagliflozin 25mg, Placebo - SIAD - Syndrome of Inappropriate Antidiuresis, Hyponatremia | Phase 2 / Phase 3 | Completed | University Hospital, Basel, Switzerland | 17 | 2017-12-15 | 2021-12-13 |
| A Multicenter Trial to Investigate the Efficacy and Safety of Tolvaptan in Patients With Hyponatremia in SIADH Tolvaptan Oral Tablet - Syndrome of Inappropriate Antidiuretic Hormone Secretion | Phase 3 | Completed | Otsuka Pharmaceutical Co., Ltd. | 16 | 2017-03-02 | 2020-11-02 |
| Effects of the SGLT2-inhibitor Empagliflozin on Patients With SIADH - the SAND Study Empagliflozin, Placebo - SIADH | Phase 2 / Phase 3 | Completed | University Hospital, Basel, Switzerland | 88 | 2016-09-05 | 2019-06-13 |
| Effects of Empagliflozin an SGLT2-Inhibitor on Healthy Volunteers With Induced Hypotonic Hyponatremia - the DIVE Study Induced hypotonic hyponatremia - SIAD model, Empagliflozin 25mg Tbl, Placebo P-Tablet - Inappropriate ADH Syndrome | Phase 2 / Phase 3 | Completed | University Hospital, Basel, Switzerland | 15 | 2016-03-01 | 2016-08-10 |
| An Observational Study to Describe the Adherence to the SEOM Algorithm for the Treatment of Hyponatraemia in Spain Hyponatremia, Syndrome of Inappropriate ADH (SIADH) Secretion | Completed | Otsuka Pharmaceutical Europe Ltd | 70 | 2015-12-01 | 2018-08-06 | |
| An Observational Study on Real-world Use and Outcomes of Patients Treated With Tolvaptan for Hyponatraemia Due to SIADH Hyponatremia, Syndrome of Inappropriate ADH (SIADH) Secretion | Completed | Otsuka Pharmaceutical Europe Ltd | 100 | 2015-11-01 | 2018-03-07 | |
| An Observational Study Measuring Outcomes in Cancer Patients Treated for Moderate to Severe Hyponatremia in Italy Hyponatremia, Syndrome of Inappropriate ADH (SIADH) Secretion | Completed | Otsuka Pharmaceutical Europe Ltd | 69 | 2015-10-01 | 2018-04-04 | |
| Tolvaptan for Patients With Acute Neurological Injuries Tolvaptan - Hyponatremia, SIADH | Not applicable | Terminated | Polderman, Kees, H., MD, PhD | 25 | 2015-08-01 | 2018-09-24 |
Showing 20 of 41. Sign in to see all of them.
Hyponatremia (30) · Diabetes Insipidus (10) · Fibrosis (2) · Stroke (2) · Subarachnoid Hemorrhage (2) · Brain Injuries, Traumatic (1) · Carcinoma, Intraductal, Noninfiltrating (1) · Frailty (1) · Heart Failure (1) · Hemorrhagic Stroke (1) · Hepatitis, Infectious Canine (1) · Hypovolemia (1) · Ischemic Attack, Transient (1) · Liver Failure (1)
Brain Diseases (41) · Central Nervous System Diseases (41) · Endocrine System Diseases (41) · Hypothalamic Diseases (41) · Metabolic Diseases (41) · Nervous System Diseases (41) · Nutritional and Metabolic Diseases (41) · Pituitary Diseases (40) · Water-Electrolyte Imbalance (40) · Female Urogenital Diseases (11) · Female Urogenital Diseases and Pregnancy Complications (11) · Kidney Diseases (11) · Male Urogenital Diseases (11) · Urogenital Diseases (11) · Urologic Diseases (11)
Tolvaptan (11) · Urea (4) · empagliflozin (4) · satavaptan (4) · Apelin (1) · Blood Specimen Collection (1) · Educational Status (1) · Standard of Care (1) · Tablets (1) · lixivaptan (1)
University Hospital, Basel, Switzerland (9) · Otsuka Pharmaceutical Development & Commercialization, Inc. (4) · Sanofi (4) · Otsuka Pharmaceutical Europe Ltd (3) · CardioKine Inc. (2) · Otsuka Pharmaceutical Co., Ltd. (2) · European Georges Pompidou Hospital (1) · Hadassah Medical Organization (1) · Helbert Rondon Berrios, MD, MS (1) · Hospital San Carlos, Madrid (1) · Insel Gruppe AG, University Hospital Bern (1) · King's College Hospital NHS Trust (1) · Mario Negri Institute for Pharmacological Research (1) · NYU Langone Health (1) · Otsuka Frankfurt Research Institute GmbH (1)
Switzerland (11) · United States (11) · Germany (9) · Spain (6) · Belgium (5) · Italy (5) · France (4) · Hungary (4) · United Kingdom (3) · Brazil (2) · Canada (2) · Czechia (2) · Denmark (2) · Hong Kong (2) · Israel (2)
Ann Dandurand, MD (1) · Beat Mueller, Prof (1) · Bruno Allolio, MD (1) · Frank Czerwiec, MD, PhD (1) · Helbert Rondon Berrios, MD. MS (1) · Isabelle Runkle, MDPhD (1) · Jan Wiegand, MD (1) · Jean-Philippe Bertocchio, MD, PhD (1) · John K Maesaka, MD (1) · Jorge G Ruiz, MD (1) · Jukka Takala, MD PhD (1) · Julie Refardt, MD (1) · Kees Polderman, MD, PhD (1)
PMID 17105757, PMID 22027579, PMID 25151571, PMID 20508186, PMID 20846604, PMID 21812576, PMID 23650556, PMID 24647802, PMID 25072816, PMID 25923040, PMID 30824558, PMID 33161846, PMID 33306187, PMID 34412521, PMID 34693505, PMID 34779837, PMID 36396331, PMID 37098131, PMID 42522233
2015 (1), 2017 (1), 2023 (1), R21DK122023 (1)